Need Help?
Copied to clipboard!

NCTN: A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation (A071102)

Study ID: A071102
NCT Number: NCT02152982

Alliance for Clinical Trials in Oncology
Submitted in collaboration with the NCTN/NCORP Data Archive

Trial Title: NCTN: A Phase II/III Randomized Trial of Veliparib or Placebo in combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation (A071102)

Trial Description: This randomized phase II/III trial studies how well temozolomide and veliparib work compared to temozolomide alone in treating patients with newly diagnosed glioblastoma multiforme. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether temozolomide is more effective with or without veliparib in treating glioblastoma multiforme.

Clinical data presented in the following publication(s):

Disease type(s): CNS Neoplasm (Primary Tumor) - Astrocytoma, High Grade

Clinical Dataset(s) included:

You are encouraged to view the PDF data dictionaries found in the "Documents" tab of the dbGaP study page, which may contain additional information regarding the data or the associated publication(s).